Placeholder Banner

Patient and Venture Philanthropy Groups Presenting at 2014 BIO Investor Forum

September 29, 2014
BIO’s alliance development team works to foster collaboration between the biotech industry and nonprofit disease foundations. In recent years, many nonprofit foundations have become more engaged in the drug development process – whether they have created clinical trial recruitment tools, established a disease registry, or funded emerging biotech companies. Recognizing the value of these initiatives to expedite research and drug development, BIO provides opportunities for venture philanthropies and patient organizations to connect with BIO members and develop partnerships that will help bring new treatments to market faster.

This year, BIO has invited four venture philanthropies to provide company presentations and participate in BIO’s One-on-One Partnering at the BIO Investor Forum on October 7-8 in San Francisco: JDRF, The Michael J. Fox foundation for Parkinson’s Research, the Leukemia & Lymphoma Society and the Rare Cancer Research Foundation. These patient organizations are dedicated to funding research that will advance therapies for the patients they serve, by collaborating with a broad range of partners and funding research at all stages of the drug development process.

About the Organizations

The Juvenile Diabetes Research Foundation (JDRF) is the leading global organization funding type 1 diabetes (T1D) research. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure T1D. As the largest charitable supporter of T1D research, JDRF is currently sponsoring $568 million in scientific research in 17 countries. In 2012 alone, JDRF provided more than $110 million to T1D research.

JDRF will be presenting on Tuesday, October 7th at 11:30 am PDT in the Marina Room.

The Michael J. Fox Foundationfor Parkinson’s Research is dedicated to finding a cure for Parkinson's disease through an aggressively funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's today.Since 2000, The Michael J. Fox Foundation has funded more than $450 million to speed a cure for Parkinson's disease.

The Michael J. Fox Foundation will be presenting on Wednesday, October 8th at 9:45 am PDT in the Marina Room.

The Leukemia & Lymphoma Society (LLS)is the world's largest voluntary (nonprofit) health organization dedicated to funding blood cancer research and providing education and patient services. LLS funds research across the continuum, from basic research through clinical trials, from bench to bedside. To date, the organization has invested more than $1 billion in research to advance therapies and save lives.

LLS will be presenting on Wednesday, October 8th at 12:00 pm PDT in the Marina Room.

The Rare Cancer Research Foundation (RCRF)is dedicated to curing rare cancers through strategic investments and innovative collaborations that facilitate effective research and accelerate deployment of promising therapies. RCRF works through existing foundations that represent rare cancer populations to present a cell-line prize to turbo charge the pace of rare cancer research, encouraging researchers to create this basic building block.

RCRF will be presenting on Tuesday, October 7th at 9:15 am PDT in the Marina Room.